Stem cell trials for cardiovascular medicine: Ethical rationale

Tissue Engineering - Part A

Volumn 20, Issue 19-20, 2014, Pages 2567-2574

  Niemansburg, Sophie L ^a   Teraa, Martin ^a   Hesam, Husna ^a   Van Delden, Johannes J M ^a   Verhaar, Marianne C ^a   Bredenoord, Annelien L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL EQUIPMENT; CELLS; CYTOLOGY; PHILOSOPHICAL ASPECTS; RISK ASSESSMENT;

BONE MARROW CELLS; CLINICAL TRIAL; HUMAN STUDY; INVASIVENESS; MEDICAL DEVICES; OUTCOME MEASURES; RANDOMIZED CONTROLLED TRIAL; SURGICAL PROCEDURES;

STEM CELLS;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CARDIOLOGY; HUMAN; INFORMED CONSENT; OUTCOME ASSESSMENT; PATIENT INFORMATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHAM PROCEDURE; STEM CELL RESEARCH; STUDY DESIGN; AUTOGRAFT; BIOETHICS; ETHICS; PROCEDURES; STEM CELL; STEM CELL TRANSPLANTATION; VASCULAR DISEASES;

AUTOGRAFTS; BIOETHICAL ISSUES; CARDIOLOGY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION; STEM CELLS; VASCULAR DISEASES;

EID: 84911886706     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2013.0332     Document Type: Article

References (70)

1. Daar, A.S., and Greenwood, H.L. A proposed definition of regenerative medicine. J Tissue Eng Regen Med 1, 179, 2007.
2. Atala, A., Lanza, R., Thomson, J., and Nerem, R. Foundations of Regenerative Medicine. San Diego, Academic Press, Elsevier, 2010.
3. Mathers, C.D., and Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3, e442, 2006.
4. Trounson, A., Thakar, R.G., Lomax, G., and Gibbons, D. Clinical trials for stem cell therapies. BMC Med 9, 52, 2011.
5. Martin, I., Baldomero, H., Bocelli-Tyndall, C., Passweg, J., Saris, D., and Tyndall, A. The survey on cellular and engineered tissue therapies in Europe in 2010. Tissue Eng Part A 18, 2268, 2012.
6. Regenberg, A.C., Hutchinson, L.A., Schanker, B., and Mathews, D.J. Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells 27, 2312, 2009.
7. Lau, D., Ogbogu, U., Taylor, B., Stafinski, T., Menon, D., and Caulfield, T. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Cell Stem Cell 3, 591, 2008.
8. Niemansburg, S.L., van Delden, J.J., Dhert, W.J., and Bredenoord, A.L. Regenerative medicine interventions for orthopedic disorders: ethical issues in the translation into patients. Regen Med 8, 65, 2013.
9. Lo, B., and Parham, L. Ethical issues in stem cell research. Endocr Rev 30, 204, 2009.
10. Magnus, D. Translating stem cell research: challenges at the research frontier. J Law Med Ethics 38, 267, 2010.
11. Trommelmans, L., Selling, J., and Dierickx, K. Ethical reflections on clinical trials with human tissue engineered products. J Med Ethics 34, e1, 2008.
12. Schneider, C.K., Salmikangas, P., Jilma, B., Flamion, B., Todorova, L.R., Paphitou, A., Haunerova, I., Maimets, T., Trouvin, J.H., Flory, E., Tsiftsoglou, A., Sarkadi, B., Gudmundsson, K., O'Donovan, M., Migliaccio, G., Ancans, J., Maciulaitis, R., Robert, J.L., Samuel, A., Ovelgonne, J.H., Hystad, M., Fal, A.M., Lima, B.S., Moraru, A.S., Turcani, P., Zorec, R., Ruiz, S., Akerblom, L., Narayanan, G., Kent, A., Bignami, F., Dickson, J.G., Niederwieser, D., Figuerola-Santos, M.A., Reischl, I.G., Beuneu, C., Georgiev, R., Vassiliou, M., Pychova, A., Clausen, M., Methuen, T., Lucas, S., Schussler-Lenz, M., Kokkas, V., Buzas, Z., MacAleenan, N., Galli, M.C., Line, A., Gulbinovic, J., Berchem, G., Fraczek, M., Menezes-Ferreira, M., Vilceanu, N., Hrubisko, M., Marinko, P., Timon, M., Cheng, W., Crosbie, G.A., Meade, N., di Paola, M.L., VandenDriessche, T., Ljungman, P., D'Apote, L., Oliver-Diaz, O., Buttel, I., and Celis, P. Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 9, 195, 2010.
13. International Society for Stem Cell Research. Guidelines for the Clinical Translation of Stem Cells. Cell Stem Cell 2, 139, 2008.
14. Anderson, J.A., and Kimmelman, J. Ethics and uncertainty: considerations for the design and review of translational trials involving stem cells. In: Hug, K., and Hermeren, G., eds. Translational Stem Cell Research. New York, NY: Humana Press, 2011, pp. 403-418.
15. Trommelmans, L., Selling, J., and Dierickx, K. Is tissue engineering a new paradigm in medicine? Consequences for the ethical evaluation of tissue engineering research. Med Health Care Philos 12, 459, 2009.
16. Sprengers, R.W., Moll, F.L., Teraa, M., and Verhaar, M.C. Rationale and design of the JUVENTAS trial for repeated intra-arterial infusion of autologous bone marrow-derived mononuclear cells in patients with critical limb ischemia. J Vasc Surg 51, 1564, 2010.
17. Moher, D., Schulz, K.F., and Altman, D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357, 1191, 2001.
18. Benoit, E., O'Donnell, T.F., Jr., Iafrati, M.D., Asher, E., Bandyk, D.F., Hallett, J.W., Lumsden, A.B., Pearl, G.J., Roddy, S.P., Vijayaraghavan, K., and Patel, A.N. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design. J Transl Med 9, 165, 2011.
19. Sprengers, R.W., Lips, D.J., Moll, F.L., and Verhaar, M.C. Progenitor cell therapy in patients with critical limb ischemia without surgical options. Ann Surg 247, 411, 2008.
20. Fisher, S.A., Doree, C., Brunskill, S.J., Mathur, A., and Martin-Rendon, E. Bone marrow stem cell treatment for ischemic heart disease in patients with no option of revascularization: a systematic review and meta-analysis. PLoS One 8, e64669, 2013.
21. Teraa, M., Sprengers, R.W., Westerweel, P.E., Gremmels, H., Goumans, M.J., Teerlink, T., Moll, F.L., and Verhaar, M.C. Bone marrow alterations and lower endothelial progenitor cell numbers in critical limb ischemia patients. PLoS One 8, e55592, 2013.
22. Kissel, C.K., Lehmann, R., Assmus, B., Aicher, A., Honold, J., Fischer-Rasokat, U., Heeschen, C., Spyridopoulos, I., Dimmeler, S., and Zeiher, A.M. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J Am Coll Cardiol 49, 2341, 2007.
23. Heeschen, C., Lehmann, R., Honold, J., Assmus, B., Aicher, A., Walter, D.H., Martin, H., Zeiher, A.M., and Dimmeler, S. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109, 1615, 2004.
24. Emanuel, E.J., Wendler, D., and Grady, C. What makes clinical research ethical? JAMA 283, 2701, 2000.
25. King, N.M. Defining and describing benefit appropriately in clinical trials. J Law Med Ethics 28, 332, 2000.
26. Kimmelman, J., and London, A.J. Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med 8, e1001010, 2011.
27. Macklin, R. The ethical problems with sham surgery in clinical research. N Engl J Med 341, 992, 1999.
28. Bishop, F.L., Adams, A.E., Kaptchuk, T.J., and Lewith, G.T. Informed consent and placebo effects: a content analysis of information leaflets to identify what clinical trial participants are told about placebos. PLoS One 7, e39661, 2012.
29. Kimmelman, J. Looking backward: a model of value for translational trials. In: Gene Transfer and the Ethics of Firstin-Human Research, Lost in Translation, 1st edition. Cambridge: University Press, 2010, pp. 89-109.
30. Hyun, I., Lindvall, O., hrlund-Richter, L., Cattaneo, E., Cavazzana-Calvo, M., Cossu, G., De, L.M., Fox, I.J., Gerstle, C., Goldstein, R.A., Hermeren, G., High, K.A., Kim, H.O., Lee, H.P., Levy-Lahad, E., Li, L., Lo, B., Marshak, D.R., McNab, A., Munsie, M., Nakauchi, H., Rao, M., Rooke, H.M., Valles, C.S., Srivastava, A., Sugarman, J., Taylor, P.L., Veiga, A., Wong, A.L., Zoloth, L., and Daley, G.Q. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 3, 607, 2008.
31. Rid, A., and Wendler, D. A framework for risk-benefit evaluations in biomedical research. Kennedy Inst Ethics J 21, 141, 2011.
32. Teraa, M., Sprengers, R.W., Leiner, T., and Verhaar, M.C. Re: angiographic demonstration of neoangiogenesis after intraarterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb ischemia. Cell Transplant 21, 1803, 2012.
33. Conte, M.S., Geraghty, P.J., Bradbury, A.W., Hevelone, N.D., Lipsitz, S.R., Moneta, G.L., Nehler, M.R., Powell, R.J., and Sidawy, A.N. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg 50, 1462, 2009.
34. Iafrati, M.D., Hallett, J.W., Geils, G., Pearl, G., Lumsden, A., Peden, E., Bandyk, D., Vijayaraghava, K.S., Radhakrishnan, R., Ascher, E., Hingorani, A., and Roddy, S. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia. J Vasc Surg 54, 1650, 2011.
35. Lawall, H., Zemmrich, C., Bramlage, P., and Amann, B. Health related quality of life in patients with critical limb ischemia. Vasa 41, 78, 2012.
36. Fregni, F., Imamura, M., Chien, H.F., Lew, H.L., Boggio, P., Kaptchuk, T.J., Riberto, M., Hsing, W.T., Battistella, L.R., and Furlan, A. Challenges and recommendations for placebo controls in randomized trials in physical and rehabilitation medicine: a report of the international placebo symposium working group. Am J Phys Med Rehabil 89, 160, 2010.
37. Diederick, E., Grobbee, and Arno, W. Hoes. Clinical Epidemiology. Principles, Methods, and Applications for Clinical Research. Jones and Bartlett Publishers, Sudbury, Massachusettes 2009.
38. Miller, F.G. Sham surgery: an ethical analysis. Sci Eng Ethics 10, 157, 2004.
39. Horng, S., and Miller, F.G. Ethical framework for the use of sham procedures in clinical trials. Crit Care Med 31, S126, 2003.
40. Swift, T., and Huxtable, R. The ethics of sham surgery in Parkinson's disease: back to the future? Bioethics 27, 175, 2013.
41. Dowrick, A.S., and Bhandari, M. Ethical issues in the design of randomized trials: to sham or not to sham. J Bone Joint Surg Am 94 Suppl 1, 7, 2012.
42. Beecher, H.K. Surgery as placebo: a quantitative study of bias. 1961. Int Anesthesiol Clin 45, 35, 2007.
43. Kaptchuk, T.J., Goldman, P., Stone, D.A., and Stason, W.B. Do medical devices have enhanced placebo effects? J Clin Epidemiol 53, 786, 2000.
44. 59th WMA General Assembly. Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects, Seoul, Republic of Korea, 2008.
45. Heckerling, P.S. Placebo surgery research: a blinding imperative. J Clin Epidemiol 59, 876, 2006.
46. Kimmelman, J. Stable ethics: enrolling non-treatmentrefractory volunteers in novel gene transfer trials. Mol Ther 15, 1904, 2007.
47. Dresser, R. First-in-human trial participants: not a vulnerable population, but vulnerable nonetheless. J Law Med Ethics 37, 38, 2009.
48. Bretzner, F., Gilbert, F., Baylis, F., and Brownstone, R.M. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 8, 468, 2011.
49. Dawson, L., Bateman-House, A.S., Mueller, A.D., Bok, H., Brock, D.W., Chakravarti, A., Greene, M., King, P.A., O'Brien, S.J., Sachs, D.H., Schill, K.E., Siegel, A., Solter, D., Suter, S.M., Verfaillie, C.M., Walters, L.B., Gearhart, J.D., and Faden, R.R. Safety issues in cell-based intervention trials. Fertil Steril 80, 1077, 2003.
50. Beauchamp, T.L., and Childress, J.F. Principles of Biomedical Ethics, Sixth edition. New York: Oxford University Press, 2009, pp. 99-148.
51. Horng, S., and Grady, C. Misunderstanding in clinical research: distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB 25, 11, 2003.
52. Henderson, G.E., Churchill, L.R., Davis, A.M., Easter, M.M., Grady, C., Joffe, S., Kass, N., King, N.M., Lidz, C.W., Miller, F.G., Nelson, D.K., Peppercorn, J., Rothschild, B.B., Sankar, P., Wilfond, B.S., and Zimmer, C.R. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med 4, e324, 2007.
53. Appelbaum, P.S., and Lidz, C.W. Therapeutic misconception. In: Emonuel, E.J., Grady, C., Crouch, R.A., Lie, R., Miller, F.G., and Wendler, D. The Oxford Textbook of Clinical Research Ethics, New York: Oxford University Press, 2008, pp. 633-644.
54. Schaeffer, M.H., Krantz, D.S., Wichman, A., Masur, H., Reed, E., and Vinicky, J.K. The impact of disease severity on the informed consent process in clinical research. Am J Med 100, 261, 1996.
55. Lidz, C.W., and Appelbaum, P.S. The therapeutic misconception: problems and solutions. Med Care 40, V55, 2002.
56. Henderson, G.E., Easter, M.M., Zimmer, C., King, N.M., Davis, A.M., Rothschild, B.B., Churchill, L.R., Wilfond, B.S., and Nelson, D.K. Therapeutic misconception in early phase gene transfer trials. Soc Sci Med 62, 239, 2006.
57. Kimmelman, J., and Levenstadt, A. Elements of style: consent form language and the therapeutic misconception in phase 1 gene transfer trials. Hum Gene Ther 16, 502, 2005.
58. Cho, M.K., and Magnus, D. Therapeutic misconception and stem cell research. Nat Reports Stem Cells 2007.
59. Gillett, G.R. Unnecessary holes in the head. IRB 23, 1, 2001.
60. Sugarman, J. Human stem cell ethics: beyond the embryo. Cell Stem Cell 2, 529, 2008.
61. Trommelmans, L., Selling, J., and Dierickx, K. Informing participants in clinical trials with ex vivo human tissueengineered products: what to tell and how to tell it? J Tissue Eng Regen Med 2, 236, 2008.
62. Ilic, D., and Polak, J. Stem cell based therapy - where are we going? Lancet 379, 877, 2012.
63. Editorial. Preventive therapy. Nature 494, 147, 2013.
64. King, N.M., Coughlin, C.N., and Furth, M.E. Ethical Issues in Regenerative Medicine, Wake Forest University Research Paper Series in Legal Studies Working Paper no.1380162; Wake Forest Intellectual Property Journal 2009, electronic copy: http://SSIN.com abstract1380162
65. Wilson, J.M. Medicine. A history lesson for stem cells. Science 324, 727, 2009.
66. Trommelmans, L. The challenge of regenerative medicine. Hastings Cent Rep 40, 24, 2010.
67. Packer, C., Boddice, B., and Simpson, S. Regenerative medicine techniques in cardiovascular disease: where is the horizon? Regen Med 8, 351, 2013.
68. Martin, P.A., Coveney, C., Kraft, A., Brown, N., and Bath, P. Commercial development of stem cell technology: lessons from the past, strategies for the future. Regen Med 1, 801, 2006.
69. Murdoch, C.E., and Scott, C.T. Stem cell tourism and the power of hope. Am J Bioeth 10, 16, 2010.
70. Taylor, P.L., Barker, R.A., Blume, K.G., Cattaneo, E., Colman, A., Deng, H., Edgar, H., Fox, I.J., Gerstle, C., Goldstein, L.S., High, K.A., Lyall, A., Parkman, R., Pitossi, F.J., Prentice, E.D., Rooke, H.M., Sipp, D.A., Srivastava, A., Stayn, S., Steinberg, G.K., Wagers, A.J., and Weissman, I.L. Patients beware: commercialized stem cell treatments on the web. Cell Stem Cell 7, 43, 2010.